Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Royalties — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Bulk rHuPH20 sales
$73.5M+172%
Proprietary product sales
$41.87M+15.2%
Device partnered product sales
$15.05M+2.6%
Device licensing and development revenue
$5.6M+64.4%
Sales-based milestones
$0-100%
Upfront license and target nomination fees
$0-100%

Similar metrics at other companies

Alkermes logo
ALKSRoyalty — Revenue
$50.73M+13.5%
Axsome Therapeutics logo
AXSMRoyalty — Revenue
$4.07M+269%
BridgeBio Pharma logo
BBIORoyalty Revenue — Revenue
$1.62M—
TEC
TECHRoyalty — Revenue
$4.97M-1.4%
TG Therapeutics logo
TGTXRoyalty — Revenue
$1.1M-35.3%
Ionis Pharmaceuticals logo
IONSRoyalty — Revenue
$58.32M-9.1%

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax?
Halozyme Therapeutics (HALO) reported royalties — revenue from contract with customer, excluding assessed tax of $240.68M in Q1 2026.
How has Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax changed year-over-year?
Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax increased by 43.1% year-over-year, from $168.19M to $240.68M.
What is the long-term trend for Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax?
Over 4 years (2021 to 2025), Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax has grown at a 43.6% compound annual growth rate (CAGR), from $203.9M to $867.84M.
What does royalties — revenue from contract with customer, excluding assessed tax mean?
The total revenue earned from royalty payments on products licensed to other companies.
How do you interpret royalties — revenue from contract with customer, excluding assessed tax?
An increase indicates higher commercial adoption of the company's licensed technology by partners, while a decrease suggests slowing sales of partner products or contract expirations.
How does royalties — revenue from contract with customer, excluding assessed tax compare across companies?
Comparable to royalty revenue streams in other biotechnology or pharmaceutical firms that utilize a licensing-based business model.